BR112021009869A2 - Óleo de canábis em pó formulado por nano-emulsificação catiônica, métodos de produção e usos deste - Google Patents

Óleo de canábis em pó formulado por nano-emulsificação catiônica, métodos de produção e usos deste

Info

Publication number
BR112021009869A2
BR112021009869A2 BR112021009869A BR112021009869A BR112021009869A2 BR 112021009869 A2 BR112021009869 A2 BR 112021009869A2 BR 112021009869 A BR112021009869 A BR 112021009869A BR 112021009869 A BR112021009869 A BR 112021009869A BR 112021009869 A2 BR112021009869 A2 BR 112021009869A2
Authority
BR
Brazil
Prior art keywords
production methods
oil powder
emulsification
cannabis oil
powder formulated
Prior art date
Application number
BR112021009869A
Other languages
English (en)
Inventor
Ezra Rafael
Larush Liraz
Magdassi Shlomo
Original Assignee
Karnak Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karnak Tech Llc filed Critical Karnak Tech Llc
Publication of BR112021009869A2 publication Critical patent/BR112021009869A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

óleo de canábis em pó formulado por nanoemulsificação catiônica, métodos de produção e usos deste. a invenção revela uma formulação sólida particular, dispersível em água, de um canabinóide ou extrato de canábis, em que estão presentes sob a forma de uma nanoemulsão, e ao dispersar-se em água, a referida formulação produz nanopartículas (gotículas de tamanho subm[icron) com um tamanho médio de até cerca de 500 nm. a presente revelação refere-se ainda a métodos de fabricação, bem como a aplicações terapêuticas em seres humanos para o tratamento de perturbações e a uma aplicação mais ampla para uma série de condições médicas.
BR112021009869A 2018-08-13 2019-03-11 Óleo de canábis em pó formulado por nano-emulsificação catiônica, métodos de produção e usos deste BR112021009869A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL261132A IL261132A (en) 2018-08-13 2018-08-13 Preparations based on cannabis oil powders produced by the nanoemulsion method, methods for their preparation and use
PCT/IL2019/050268 WO2020035850A1 (en) 2018-08-13 2019-03-11 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof

Publications (1)

Publication Number Publication Date
BR112021009869A2 true BR112021009869A2 (pt) 2022-05-17

Family

ID=63998426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021009869A BR112021009869A2 (pt) 2018-08-13 2019-03-11 Óleo de canábis em pó formulado por nano-emulsificação catiônica, métodos de produção e usos deste

Country Status (10)

Country Link
US (2) US11712430B2 (pt)
EP (1) EP3716946A1 (pt)
JP (1) JP2021535935A (pt)
CN (1) CN113473965A (pt)
AU (1) AU2019322212B2 (pt)
BR (1) BR112021009869A2 (pt)
CA (1) CA3086887A1 (pt)
CO (1) CO2021007647A2 (pt)
IL (2) IL261132A (pt)
WO (1) WO2020035850A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020220141A1 (en) * 2019-05-02 2020-11-05 Betterlife Pharma Inc. Cannabinoid stock transdermal formulations
US10780075B1 (en) 2019-07-31 2020-09-22 Etain IP, LLC Water soluble cannabis composition
CA3149966A1 (en) * 2019-08-12 2021-02-18 Tenshi Kaizen Private Limited Cannabidiol orally disintegrating tablets
IL295386A (en) * 2020-07-29 2022-10-01 Karnak Tech Llc Improved formulations of lipophilic substances for cosmetic uses
CN115843242A (zh) 2020-07-29 2023-03-24 卡纳克科技有限责任公司 亲脂性膳食补充剂、营养品和有益食用油的口服组合物
WO2022024127A1 (en) 2020-07-29 2022-02-03 Karnak Technologies, Llc Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives
EP4196112A1 (en) * 2020-08-14 2023-06-21 Capheads LLC Dosing capsule made from cannabis-derived resin and methods of making the same
CA3114085A1 (en) * 2021-04-05 2022-10-05 MEC11S Inc. Composition comprising cannabis extracts and method of manufacturing same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011210352A1 (en) * 2010-01-26 2012-08-09 Radikal Therapeutics Inc. Compositions and methods for prevention and treatment of pulmonary hypertension
US8629177B2 (en) * 2010-08-24 2014-01-14 Aphios Corporation Nanoencapsulated delta-9-tetrahydrocannabinol
ES2739194T3 (es) 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
AU2013263292B2 (en) 2012-05-16 2018-03-08 Maninder SANDHU Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
WO2015171445A1 (en) 2014-05-06 2015-11-12 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
US20160058866A1 (en) 2014-09-02 2016-03-03 Ronald D. Sekura Alternative solutions for the administration of cannabis derived botanical products
US9629886B2 (en) 2015-02-24 2017-04-25 Ers Holdings, Llc Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil
AU2016231788A1 (en) 2015-03-19 2017-10-12 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
EP3368014B1 (en) * 2015-10-26 2023-10-04 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Novel cannabinoid formulations
JP2019511580A (ja) 2016-04-15 2019-04-25 エスアールイー ウェルネス インク．Ｓｒｅ Ｗｅｌｌｎｅｓｓ Ｉｎｃ． 乳化剤を使用して大麻油を親水性にする方法及び関連するカンナビノイド組成物

Also Published As

Publication number Publication date
US20230321031A1 (en) 2023-10-12
US20210059975A1 (en) 2021-03-04
AU2019322212A1 (en) 2021-04-08
IL261132A (en) 2018-11-04
CO2021007647A2 (es) 2021-08-30
WO2020035850A1 (en) 2020-02-20
AU2019322212B2 (en) 2022-09-29
JP2021535935A (ja) 2021-12-23
CA3086887A1 (en) 2020-02-20
US11712430B2 (en) 2023-08-01
EP3716946A1 (en) 2020-10-07
IL275430A (en) 2020-08-31
CN113473965A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
BR112021009869A2 (pt) Óleo de canábis em pó formulado por nano-emulsificação catiônica, métodos de produção e usos deste
CR20210483A (es) Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
BR112014026424A2 (pt) composto, processo para produzir um composto de di-idrato, composto de benzotiofeno, método para prevenir e/ou tratar uma doença, e, composição farmacêutica
BR112019001794A2 (pt) composição de cannabis
BR112017011440A2 (pt) uma composição antimicrobiana
BR112015020049A8 (pt) composição na forma de uma emulsão óleo-em-água e processos cosméticos
BR112017012932A2 (pt) emulsão, processo de preparação de emulsão, uso das partículas compostas e processo de tratamento cosmético de material queratínico
BR112015021057A2 (pt) método e aparelho para formar uma parte, e, parte formada a quente
BR112017021191A2 (pt) um extrato de indigo naturalis e um processo para preparar o mesmo
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.
BR112019004499A2 (pt) implante compreendendo um pó compósito contendo sal de cálcio tendo partículas microestruturadas
BR112017025631A2 (pt) composições oftálmicas aquosas, método de induzir ou aumentar a formação de lágrima, método de formação de aglomerados de ciclosporina a e uso de ciclosporina a
CL2020003374A1 (es) Composicion y metodo de cannabinoides para tratar el tept y/o la ansiedad
ECSP19018116A (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
BR112017024304A2 (pt) processo para a preparação de um extrato de cérebro animal
BR112014031706A2 (pt) composição farmacêutica oral; forma de composição farmacêutica oral; método de redução de efeito de alimento de itraconazol em um indivíduo; método de redução de variabilidade em um mesmo indivíduo de itraconazol; método de redução de variabilidade entre indivíduos de itraconazol; método de tratamento de onicomicose; método de tratamento de uma doença ou afecção e método de tratamento de câncer
AR075686A1 (es) Nanoparticulas de policosanol
BR112018009618A8 (pt) processo para fabricação de uma dispersão aquosa compreendendo farelo de mostarda, emulsão de óleo em água e processo de fabricação de uma emulsão de óleo em água
CO2018009412A2 (es) Grafeno y la producción de grafeno
CL2016003376A1 (es) Metodo de preparacion de un catalizador de nanoparticulas de cu2o/tio2; y catalizador de nanoparticulas de cu2o/tio2
BR112016029749A8 (pt) composição para perda de peso, composição que compreende cinamaldeído e zinco, seus usos, e método para fabricação de umm produto alimentício
BR112017028378A2 (pt) chocolate em pó aglomerado solúvel
BR112018070885A2 (pt) método de controlar um arranjo de acoplamento em uma caixa de engrenagens
Gentile Interpreting Democracy: Public Service Interpreters as Drivers of Democratisation

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]